Results 191 to 200 of about 53,159 (257)

Immune checkpoint inhibitor‐induced arrhythmias: Mechanistic insights from clinical and preclinical studies

British Journal of Pharmacology, EarlyView.
Immune checkpoint inhibitors (ICIs) have transformed cancer therapy, but their efficacy continues to be limited by immune‐related adverse events. Among these, ICI‐induced cardiac arrhythmias are increasingly recognised as a major adverse reaction, encompassing a broad spectrum of clinical phenotypes, including conduction blocks, atrial fibrillation and
Anand R. Ramalingam, Zoltán Márton Köhler, Péter Ferdinandy, Zoltán V. Varga   +3 more
wiley   +1 more source

Cytotoxic CD4 T Cells: Dual Agents in HIV-1 Pathogenesis and Persistence. [PDF]

Curr HIV/AIDS Rep
Mickens KL, Dillon SM, Guo K, Wilson CC, Santiago ML.   +4 more
europepmc   +1 more source

CD93—An emerging vascular target in cancer therapy

British Journal of Pharmacology, EarlyView.
Abstract CD93 is a single‐pass transmembrane glycoprotein that belongs to the C‐type lectin domain group XIV family of proteins. Although it is known to be expressed in other cell types, namely, in some subsets of immune cells, CD93 is primarily expressed on endothelial cells, where it acts as a crucial regulator of angiogenesis.
Beatriz de Alves Pereira, Stefano Barbera, Roberta Lugano, Anna Dimberg   +3 more
wiley   +1 more source

IL-15 promotes immune escape, invasion, and metastasis of pancreatic cancer by upregulating PD-L1 expression via the JAK1/STAT1/IRF1 pathway. [PDF]

Cell Commun Signal
Ning J, Wei X, Li H, Li Q, Jiang H, Chen X, Zhang W.   +6 more
europepmc   +1 more source

Bruton tyrosine kinase inhibitors and cardiovascular adverse events

British Journal of Pharmacology, EarlyView.
Abstract Bruton tyrosine kinase inhibitors (BTKi) have transformed the management of chronic lymphocytic leukaemia and other B‐cell malignancies, yet their therapeutic benefit is tempered by clinically relevant cardiovascular toxicities (predominantly atrial fibrillation, hypertension, bleeding and ventricular arrhythmias).
Massimiliano Camilli, Cristina Madaudo, Emanuela Salvatorelli, Giorgio Minotti, Pierantonio Menna   +4 more
wiley   +1 more source

Metabolic [¹⁸F]F-AraG PET imaging of T Cell activation: a functional complement to cell-specific immune tracers. [PDF]

EJNMMI Res
Almutairi WM, Gopaulchan M, Bhaskara R, Zheng QH, Ocana JA, Langer M, Kuruvilla TP, Durm G, Oderinde OM.   +8 more
europepmc   +1 more source

Ezh2 Inhibits the Differentiation of Short‐Lived Effector CD8+ T Cells and Promotes T Cell‐Dependent Antitumor Immunity

Cancer Science, EarlyView.
The antitumor immune response is attenuated in T cell‐specific Ezh2 knockout mice. ABSTRACT Appropriate regulation of the differentiation balance between effector CD8+ T cells and memory CD8+ T cells is crucial for an appropriate immune response. We previously reported that the tumor suppressor menin suppresses the differentiation of CD8+ T cells into ...
Kenji Takagi, Junpei Suzuki, Yuko Matsuoka, Makoto Kuwahara, Taro Oshikiri, Masakatsu Yamashita   +5 more
wiley   +1 more source

CD8+ T cells in Hashimoto's thyroiditis-associated papillary thyroid carcinoma. [PDF]

Eur Thyroid J
Wang L, Zhang L, Chen J, Wang D, Zhang Y, Sun L, Su W, Li M, Zhou Q, Wang J, Jiang J.   +10 more
europepmc   +1 more source

Hypericin Suppresses Liver Cancer Through Autophagic Degradation of AKT and Eliciting Antitumor Immune Response

Cancer Science, EarlyView.
Hypericin induces autophagic AKT degradation by promoting AKT‐HSPA5 interaction in an S473 phosphorylation‐dependent manner, suppressing HCC growth. It enhances CD8+ T cell‐mediated antitumor immunity and synergizes with anti‐PD‐L1 therapy, showing favorable safety for HCC treatment. ABSTRACT Hepatocellular carcinoma (HCC) is the most prevalent primary
Sien Ma, Qianqian Xu, Mengjuan Zhu, Xianming Ge, Jian Xu, Yan Pan, Mengli Wang, Yuting Zhu, Aoxuan Xu, Hanmeng Liu, GuangHai Xiang, Weipeng Gong, Bao Zhao   +12 more
wiley   +1 more source

FDX1 Depletion Activates CD8+ T Cell Antitumor Immunity by Promoting DMBT1 Secretion in Cuproptosis of Colorectal Cancer

Cancer Science, EarlyView.
Elesclomol‐induced cuproptosis potently activates both innate and adaptive antitumor immunity, especially CD8+ T cell immunity. FDX1 serves as a central regulator of CD8+ T cell functionality through DMBT1 downregulation during cuproptosis in colorectal cancer.
Jieqiong Wu, Zaixi Lian, Mingzhou Li, Xingtu Qin, Xiaoyu Lei, Lihua Yang, Lin Bing, Qiuyue Li, Lingyan Zhou, Zhiyang Ma, Xuemei Xu, Jinghao Huang, Zilong Chen, Lijie Chen, Lingjie Zhang, Zhiyuan Xiao, Xiangyu Jian, Xiaoqin Zhang, Yanqing Ding, Yaping Ye, Li Liang, Hongli Jiao, Shuyang Wang   +22 more
wiley   +1 more source